The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02459977

Enrollment

Registered

2015-06-02

Start date

2012-04-30

Completion date

Unknown

Last updated

2015-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Brief summary

Basiliximab has been a routine induction therapeutic agent even for well-matched living kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is a different drug from cyclosporine, the investigators study the usefulness of tacrolimus-based immunosuppression without basiliximab in well matched living KT.

Detailed description

The investigators omit basiliximab induction therapy in patients who underwent one to three-HLA mismatched living donor renal transplantation. Participants should receive ABO compatible and T-flow negative transplants. The investigators compare the results of intervention group with conventionally treated control group (age and sex matched patient who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy).

Interventions

DRUGBasiliximab

Basiliximab induction therapy

DRUGNo basiliximab

No basiliximab induction therapy

PROCEDUREKidney transplantation

kidney transplantation

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ABO compatible and T-flow negative transplants * Living kidney transplantation * Tacrolimus based immunosuppression

Exclusion criteria

* Multiorgan transplantation * Zero-mismatch transplantation (we use cyclosporine instead of FK506)

Design outcomes

Primary

Measure	Time frame	Description
Incidence of rejection	within 3 years	The investigators measures incidence of rejection by serum creatinine, urinalysis and kidney allograft biopsy.

Secondary

Measure	Time frame	Description
Incidence of infection	postoperative 6 month, 1 year, 1.5 year, 2 years and 3 years	The investigators measures incidence of infection such as CMV, BKV infection, pneumonia, urinary tract infection and other infections.

Countries

South Korea

Contacts

Primary ContactChung Hee Baek, M.D.

bch393@naver.com82-2-3010-1481

Backup ContactSu-Kil Park, M.D, PhD

82-2-3010-3263

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026